RxDoctor Payments Data

Scott Edele, DO

Family Medicine · Margate, FLNPI 1710392584

Payments from drug & device makers

$4,013in general payments, 2019–2025

Across 218 payments — averaging $18.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$647
  • AstraZeneca$614
  • Novo Nordisk$538
  • Boehringer Ingelheim$383
  • Amgen$303
  • Lilly USA, LLC$261
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$4,013100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,013 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,263
Medicare patients
122
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate24$27,695
OzempicSemaglutide20$19,010
FarxigaDapagliflozin Propanediol15$13,131
EliquisApixaban13$11,642
Spiriva HandihalerTiotropium Bromide12$7,311
SynthroidLevothyroxine Sodium24$2,436
Levothyroxine Sodium113$1,068
Rosuvastatin Calcium85$969
Amlodipine Besylate121$887
Lisinopril87$875
Atorvastatin Calcium83$805
Losartan Potassium62$722
Bupropion XlBupropion Hcl20$718
Albuterol Sulfate HfaAlbuterol Sulfate23$629
Simvastatin50$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$48$27,69524 claims
Novo NordiskOzempic$538$19,01020 claims
AstraZenecaFarxiga$614$13,13115 claims
PfizerEliquis$110$11,64213 claims
AbbVieSynthroid$647$2,43624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Margate

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →